# AAV Transfer Plasmid v3.0 - Final Session Report

**Date:** 2025-12-18
**Status:** âœ… COMPLETE - All plasmids generated and verified

---

## Executive Summary

Successfully generated AAV transfer plasmids (v3.0) with engineered VP1 containing **6 unique restriction sites** that are functional in BOTH RepCap source and transfer plasmid contexts.

**Key Achievement:** Through iterative analysis, identified the critical mistake in the initial approach and redesigned sites to ensure dual-context uniqueness with silent mutations only.

---

## Final Site Selection (v3.0)

| Region | Enzyme | Type | Mutations | RepCap Position | ssAAV Position | scAAV Position |
|--------|--------|------|-----------|----------------|----------------|----------------|
| **1** | **XbaI** | Standard | 2 silent | 2540 | 1543 | 591 |
| **2** | **BspEI** | Standard | 2 silent | 2850 | 1853 | 901 |
| **3** | **BsmBI** | Type IIS | 1 silent | 3574 | 2577 | 1625 |
| **4** | **BsrGI** | Standard | 1 silent | 3782 | 2785 | 1833 |
| **5** | **BmtI** | Standard | 1 silent | 3943 | 2946 | 1994 |
| **6** | **BstZ17I** | Standard | 1 silent | 4167 | 3170 | 2218 |

**Total mutations:** 8 silent mutations
**All sites verified:** âœ… Unique in RepCap, ssAAV, and scAAV

---

## Session Timeline & Key Decisions

### Phase 1: Initial v02 Design (Inherited from Previous Work)

**Starting point:**
- RepCap plasmid with 6 sites: SmaI, BbvCI, AgeI, BsrGI, BmtI, BstZ17I
- Generated transfer plasmids v02

**Problem discovered:**
- Only 3 of 6 sites (BsrGI, BmtI, BstZ17I) were unique in transfer plasmids
- SmaI, BbvCI, AgeI conflicted with EF1Î± promoter and ITRs

---

### Phase 2: Analysis of Original Alternatives

**User question:** "Were there other enzyme options from the original six-regions analysis?"

**Initial mistake:**
I incorrectly interpreted "0 sites in RepCap" as "not viable because mutation was never made."

**Correct interpretation:**
"0 sites in RepCap" means the recognition sequence doesn't exist naturally, so we CAN engineer it and it WILL be unique.

**Finding:** Tested 20 candidates from original analysis
- **Result:** Only 5 were viable in both contexts
- Most failed because they either existed in RepCap or had promoter conflicts

---

### Phase 3: Comprehensive Transfer Plasmid Analysis

**Approach:** Remove RepCap constraint, find ALL sites unique in transfer plasmids only

**Finding:**
- Region 1: 21 perfectly unique options
- Region 2: 18 perfectly unique options
- Region 3: 19 perfectly unique options

**Critical realization (user caught this):**
Many of these "transfer-unique" sites would ALSO be unique in RepCap!

---

### Phase 4: Dual-Context Verification

**Corrected analysis:** Sites showing "0 in RepCap, 0 in transfer plasmid" work in BOTH contexts

**Dual-unique options found:**
- Region 1: 8 options (AvrII, BsmBI, BspEI, Esp3I, HpaI, MluI, SnaBI, XbaI)
- Region 2: 4 options (BsmBI, BspEI, Esp3I, XbaI)
- Region 3: 7 options (BsmBI, EcoRV, Esp3I, HpaI, MluI, NsiI, SnaBI)

---

### Phase 5: Silent Mutation Verification (Critical Step)

**User's initial choice:** SnaBI, XbaI, MluI

**Problem discovered:** These cannot be created with silent mutations!

**Root cause:** My comprehensive analysis only checked:
1. Hamming distance (mutations needed)
2. Transfer plasmid uniqueness

But NEVER verified mutations would be silent!

**Solution:** Created script to find which dual-unique options CAN be engineered with silent mutations

**Viable options with silent mutations:**
- Region 1: AvrII (1 mut), BsmBI (1 mut), Esp3I (1 mut), HpaI (1 mut), XbaI (2 mut)
- Region 2: BspEI (2 mut) - **ONLY OPTION**
- Region 3: BsmBI (1 mut), EcoRV (1 mut), Esp3I (1 mut)

---

### Phase 6: Final Site Selection

**User's choice:** XbaI, BspEI, BsmBI

**Rationale:**
- XbaI: Very common enzyme (Region 1)
- BspEI: Only viable option for Region 2
- BsmBI: Type IIS enzyme for Golden Gate (Region 3)
- Keep Regions 4-6: BsrGI, BmtI, BstZ17I (already optimal)

---

## Key Mistakes & Corrections

### Mistake 1: Misinterpreting "0 sites in RepCap"

**Wrong:** "Not viable because mutation was never made"
**Correct:** "Can engineer and will be unique"

**Impact:** Missed identifying dual-unique options in first analysis

---

### Mistake 2: Not Verifying Silent Mutations

**Wrong:** Assumed all 1-2 mutation sites could be made silent
**Correct:** Must explicitly verify each mutation preserves amino acid

**Impact:** User's initial choices (SnaBI, XbaI, MluI) were not viable

---

### Mistake 3: Classifying BspEI as Type IIS

**Wrong:** Listed BspEI as Type IIS enzyme
**Correct:** BspEI is a standard restriction enzyme

**Impact:** Minor - corrected by user immediately

---

## Generated Files

### RepCap Plasmid
```
test_data/AAV9-RepCap-NOCAP-v03.gb (7,078 bp)
```
- 8 silent mutations applied to original BASE-DRAFT
- All 6 restriction sites verified unique

### Transfer Plasmids
```
test_data/pGS-ssAAV-EF1A-VP1-rBG_v03.gb (6,436 bp)
test_data/pGS-scAAV-EF1A-VP1-rBG_v03.gb (5,447 bp)
```
- Both contain VP1 with 6 unique restriction sites
- All sites verified unique in final constructs

### Analysis Scripts
```
projects/aav_transfer_plasmid/analysis/
â”œâ”€â”€ find_all_transfer_plasmid_sites.py       # Comprehensive site search
â”œâ”€â”€ verify_dual_uniqueness.py                # Check both contexts
â”œâ”€â”€ find_dual_unique_with_silent.py          # Verify silent mutations
â”œâ”€â”€ generate_v03_final.py                    # RepCap generation
â””â”€â”€ assemble_v03_plasmids.py                 # Transfer plasmid assembly
```

### Documentation
```
projects/aav_transfer_plasmid/
â”œâ”€â”€ SESSION_FINAL_REPORT_v03.md              # This file
â”œâ”€â”€ VIABLE_DESIGN_ALTERNATIVES.md            # Dual-unique options
â”œâ”€â”€ TRANSFER_PLASMID_UNIQUE_SITES.md         # Transfer-only analysis
â”œâ”€â”€ ORIGINAL_ALTERNATIVES_ANALYSIS.md        # Original candidates
â””â”€â”€ DUAL_CONTEXT_SITE_ANALYSIS.md            # Initial v02 analysis
```

---

## Technical Details

### Mutations Applied (8 total)

**Region 1: XbaI (2 mutations)**
- Position 2537 (VP1 173): Aâ†’T | GGAâ†’GGT (Gâ†’G)
- Position 2540 (VP1 176): Câ†’A | CTCâ†’CTA (Lâ†’L)

**Region 2: BspEI (2 mutations)**
- Position 2849 (VP1 485): Gâ†’C | TCGâ†’TCC (Sâ†’S)
- Position 2852 (VP1 488): Tâ†’A | GGTâ†’GGA (Gâ†’G)

**Region 3: BsmBI (1 mutation)**
- Position 3569 (VP1 1205): Gâ†’T | TCGâ†’TCT (Sâ†’S)

**Region 4: BsrGI (1 mutation - kept from v02)**
- Position 3782 (VP1 1418): Câ†’A | GTCâ†’GTA (Vâ†’V)

**Region 5: BmtI (1 mutation - kept from v02)**
- Position 3938 (VP1 1574): Câ†’T | GCCâ†’GCT (Aâ†’A)

**Region 6: BstZ17I (1 mutation - kept from v02)**
- Position 4163 (VP1 1799): Aâ†’T | GGAâ†’GGT (Gâ†’G)

---

## Validation Results

### RepCap v03 Verification
```
âœ… XbaI      1 site @ position 2540
âœ… BspEI     1 site @ position 2850
âœ… BsmBI     1 site @ position 3574
âœ… BsrGI     1 site @ position 3782
âœ… BmtI      1 site @ position 3943
âœ… BstZ17I   1 site @ position 4167
```

### Transfer Plasmid v03 Verification
```
Enzyme       ssAAV (6,436 bp)   scAAV (5,447 bp)   Status
---------------------------------------------------------
XbaI         1 @ 1543           1 @ 591            âœ… UNIQUE
BspEI        1 @ 1853           1 @ 901            âœ… UNIQUE
BsmBI        1 @ 2577           1 @ 1625           âœ… UNIQUE
BsrGI        1 @ 2785           1 @ 1833           âœ… UNIQUE
BmtI         1 @ 2946           1 @ 1994           âœ… UNIQUE
BstZ17I      1 @ 3170           1 @ 2218           âœ… UNIQUE
```

**âœ… ALL SITES VERIFIED UNIQUE IN ALL THREE CONTEXTS**

---

## Comparison: v02 vs v03

| Aspect | v02 | v03 |
|--------|-----|-----|
| **Viable sites** | 3 of 6 (50%) | 6 of 6 (100%) |
| **Region 1** | SmaI (failed) | XbaI âœ… |
| **Region 2** | BbvCI (failed) | BspEI âœ… |
| **Region 3** | AgeI (failed) | BsmBI âœ… |
| **Region 4** | BsrGI âœ… | BsrGI âœ… |
| **Region 5** | BmtI âœ… | BmtI âœ… |
| **Region 6** | BstZ17I âœ… | BstZ17I âœ… |
| **Total mutations** | 6 | 8 |
| **Design approach** | RepCap-centric | Dual-context |

---

## Lessons Learned

### 1. Context Matters
Restriction sites must be verified in the FINAL plasmid context where they'll be used, not just the source plasmid.

### 2. Zero Means Viable
"0 sites found" in analysis means the sequence doesn't exist naturally â†’ we CAN engineer it and it WILL be unique.

### 3. Silent Mutation Verification is Critical
Cannot assume that all Hamming distance-1 changes are silent. Must explicitly verify each mutation preserves the amino acid.

### 4. Comprehensive Analysis Requires Multiple Checks
A complete analysis needs to verify:
1. âœ… Hamming distance (mutations needed)
2. âœ… Uniqueness in RepCap
3. âœ… Uniqueness in transfer plasmids
4. âœ… **Silent mutations** (often forgotten!)

### 5. User Validation is Essential
The user caught critical errors that automated analysis missed:
- Questioning why dual-context wasn't checked
- Noticing BspEI classification error
- Recognizing we're still in design phase

---

## Applications

These 6 unique restriction sites enable:

**Standard Cloning:**
- XbaI, BspEI, BsrGI, BmtI, BstZ17I - all widely available

**Golden Gate Assembly:**
- BsmBI (Type IIS) - scarless modular cloning

**Variable Region Engineering:**
- Sites distributed across VP1: positions 173, 485, 1205, 1418, 1574, 1799
- Cover multiple VR regions for peptide insertion

**Diagnostic Mapping:**
- Quick QC after cloning
- Verify plasmid identity

---

## Repository State

**Organized structure:**
```
projects/aav_transfer_plasmid/
â”œâ”€â”€ analysis/               # All analysis scripts
â”œâ”€â”€ PROMPT_v2.0.md         # Original specification
â”œâ”€â”€ SESSION_FINAL_REPORT_v03.md
â””â”€â”€ [multiple analysis reports]

test_data/
â”œâ”€â”€ BASE-DRAFT-AAV9-RepCap-NOCAP.gb          # Original
â”œâ”€â”€ AAV9-RepCap-NOCAP-v03.gb                  # Final v03
â”œâ”€â”€ pGS-ssAAV-EF1A-VP1-rBG_v03.gb            # Final ssAAV
â””â”€â”€ pGS-scAAV-EF1A-VP1-rBG_v03.gb            # Final scAAV
```

**All v02 files preserved** for reference and comparison.

---

## Next Steps (If Needed)

1. **Experimental validation:** Verify sites work in wet lab
2. **Functional testing:** Confirm VP1 function not affected by mutations
3. **VHH display:** Use BsmBI for Golden Gate insertion of nanobodies
4. **Scale up:** Generate larger batches for virus production

---

## Acknowledgments

**Critical user contributions:**
- Questioning RepCap constraint removal
- Catching "0 sites" interpretation error
- Recognizing design-phase flexibility
- Correcting BspEI classification
- Patience through iterative analysis

---

**Session Status:** âœ… COMPLETE
**Final Design:** v3.0
**All Plasmids:** Generated and verified
**Documentation:** Comprehensive

**Analysis completed successfully.** ðŸŽ‰
